SCHEMBL5638355

SCHEMBL5638355

O=CN[C@H]1CCCCN(C(=O)Nc2cccc(F)c2)C1=O

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 3/20 0.49
▸ MAPT P10636 1/20 0.47
▸ KMT2A Q03164 3/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ GAA P10253 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.45
▸ USP2 O75604 5/20 0.44
▸ ALDH1A1 P00352 5/20 0.44
▸ CYP2D6 P10635 4/20 0.44
▸ CYP2C19 P33261 2/20 0.43
▸ CYP3A4 P08684 4/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CYP2C9 P11712 1/20 0.42
▸ ALOX15 P16050 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5637037 0.86 KMT2A (0.49) NPC1MAPTKMT2ASMN1; SMN2RAB9A
SCHEMBL5640334 0.86 SMN1; SMN2 (0.46) NPC1MAPTSMN1; SMN2RAB9AGAA
SCHEMBL5637671 0.86 NPC1 (0.53) NPC1MAPTKMT2ASMN1; SMN2RAB9A
SCHEMBL5638348 0.85 NPC1 (0.49) NPC1MAPTKMT2ASMN1; SMN2RAB9A
SCHEMBL5638456 0.82 NPC1 (0.50) NPC1MAPTKMT2ASMN1; SMN2RAB9A
SCHEMBL5638425 0.80 KMT2A (0.43) NPC1KMT2ASMN1; SMN2RAB9AMEN1
SCHEMBL5638864 0.80 NPC1 (0.49) NPC1MAPTKMT2ASMN1; SMN2RAB9A
SCHEMBL5640450 0.77 COL1A1 (0.41) MAPTNPSR1ALDH1A1CYP2D6CYP2C19
SCHEMBL5638131 0.74 ALDH1A1 (0.38) MAPTKMT2ASMN1; SMN2RAB9AMEN1
SCHEMBL5637709 0.73 POLB (0.35) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220856-B2 Substituted quinoline CCR5 receptor antagonists SCHERING AKTIENGESELLSCHAFT (DE) 2007-05-22 — — US disclosed
EP-1534681-A1 SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS SCHERING AKTIENGESELLSCHAFT (DE) 2005-06-01 — — EP disclosed
US-20040072818-A1 Substituted quinoline CCR5 receptor antagonists SCHERING AKTIENGESELLSCHAFT (DE) 2004-04-15 — — US disclosed
WO-2004002960-A1 SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS SCHERING AKTIENGESELLSCHAFT (DE) 2004-01-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072818-A1 Substituted quinoline CCR5 receptor antagonists CCR5, CXCR3, CCR2 NPC1 449/4885MAPT 4213/4885KMT2A 3541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback